secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024981
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q3 rev down 14% to $66M; raises FY22 revenue guidance to $460-480M
-------------------------------------------------------------------------

- Total revenue $66M (down 14% YoY); Foundry $25M (down 29%), Biosecurity $42M (down 3%).
- Operating loss $(653)M includes $563M stock-based comp; Adj EBITDA $(70)M vs $(18)M prior year.
- Added 15 new Cell Programs (50% growth); cash & equivalents over $1.3B.
- Completed Zymergen, Bayer West Sac, Altar, and Circularis acquisitions in October.
- FY22 guidance raised: total rev $460-480M (from $425-440M), Biosecurity at least $310M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/0000950170-22-024981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/dna-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer